摘要
目的:观察拉米夫定联合胸腺肽α1治疗慢性乙型肝炎(CHB)的疗效。方法:联合治疗组:用拉米夫定〔葛兰素史克(苏州)公司生产〕,疗程12个月;拉米夫定治疗开始时给予胸腺肽α1(海南双成药业生产)1.6mg/次,皮下注射,每周2次,连续6个月。对照组仅给拉米夫定100mg/d口服,疗程12个月。两组病例治疗结束后均随访12个月,于治疗开始后1、3、6、12个月,及随访期3、6、12个月进行评估及实验室检查,观察肝功能、HBVM、血常规、肾功能,HBV-DNA定量。结果:(1)两组患者治疗期间ALT均得到良好的复常,复常率联合组稍高,但无统计学明显差异。随访期内6个月和12个月ALT复常率联合治疗组与拉米夫定组比较有显著差异。(2)两组患者治疗期间HBV-DAN阴转率都达到较高比率,无统计学明显差异。(3)两组患者治疗期间及随访期内血清HBeAg/抗-HBe转换率,联合治疗组与拉米夫定组比较有显著差异。结论:拉米夫定联合胸腺肽α1治疗CHB的确具有协同抗HBV效应。
Objective：To observe the effect of combined application Lamivudine and Thymosin ch in treating patients with chronic hepatitis B （CHB） .Methods：32 patients of CHB with positive HBeAg HBV- DNA were divided into two groups. Group A was treated with Lamivudine plus Thymosin α1, and group B with Lamivudine. The serum HBeAg/anti - HBe HBV - DNA, hepatic biological paranmeters were observed. Results：The positive rate of HBeAg/anti - HBe in group A higher than these in group B（ P 〈 0.05） after 52 weeks treatment. Conclusion： Combined application of Lamivudine and Thymosin α1 can enhance the therapeutic effect in treating CHB.
出处
《医学理论与实践》
2006年第4期389-390,共2页
The Journal of Medical Theory and Practice
